Targeted strategies directed at the molecular defect: Toward precision medicine for select primary immunodeficiency disorders

Journal of Allergy and Clinical Immunology

Volumn 139, Issue 3, 2017, Pages 715-723

  Notarangelo, Luigi D ^a   Fleisher, Thomas A ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

autoimmunity; immune dysregulation; mutation; Personalized medicine; primary immunodeficiency disorders; therapy

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE DELTA SYNDROME; STAT1 PROTEIN; STAT3 PROTEIN; UNCLASSIFIED DRUG; CARRIER PROTEIN; CHOLINE TRANSPORTER-LIKE PROTEIN 4, HUMAN; LRBA PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; STAT1 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN;

CLINICAL FEATURE; HAPLOINSUFFICIENCY; HUMAN; IMMUNE DEFICIENCY; IMMUNOGLOBULIN DEFICIENCY; LIPOPOLYSACCHARIDE RESPONSIVE AND BEIGE LIKE ANCHOR PROTEIN DEFICIENCY; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); MUTATION; MYELOKATHEXIS SYNDROME; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTEIN DEFICIENCY; REVIEW; VERRUCA VULGARIS; AGAMMAGLOBULINEMIA; GENETICS; INFECTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AGAMMAGLOBULINEMIA; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFECTION; MEMBRANE TRANSPORT PROTEINS; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PRECISION MEDICINE; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; WARTS;

EID: 85025075143     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2017.01.004     Document Type: Review

References (67)

1. Picard, C., Al-Herz, W., Bousfiha, A., Casanova, J.L., Chatila, T., Conley, M.E., et al. Primary Immunodeficiency Diseases: an Update on the Classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015. J Clin Immunol 35 (2015), 696–726.
2. Angulo, I., Vadas, O., Garcon, F., Banham-Hall, E., Plagnol, V., Leahy, T.R., et al. Phosphoinositide 3-kinase delta gene mutation predisposes to respiratory infection and airway damage. Science 342 (2013), 866–871.
3. Lucas, C.L., Kuehn, H.S., Zhao, F., Niemela, J.E., Deenick, E.K., Palendira, U., et al. Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110delta result in T cell senescence and human immunodeficiency. Nat Immunol 15 (2014), 88–97.
4. Elgizouli, M., Lowe, D.M., Speckmann, C., Schubert, D., Hulsdunker, J., Eskandarian, Z., et al. Activating PI3Kdelta mutations in a cohort of 669 patients with primary immunodeficiency. Clin Exp Immunol 183 (2016), 221–229.
5. Deau, M.C., Heurtier, L., Frange, P., Suarez, F., Bole-Feysot, C., Nitschke, P., et al. A human immunodeficiency caused by mutations in the PIK3R1 gene. J Clin Invest 124 (2014), 3923–3928.
6. Lucas, C.L., Zhang, Y., Venida, A., Wang, Y., Hughes, J., McElwee, J., et al. Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K. J Exp Med 211 (2014), 2537–2547.
7. Coulter, T.I., Chandra, A., Bacon, C.M., Babar, J., Curtis, J., Screaton, N., et al. Clinical spectrum and features of activated phosphoinositide 3-kinase delta syndrome: a large patient cohort study. J Allergy Clin Immunol, 2016 [Epub ahead of print]. http://dx.doi.org/10.1016/j.jaci.2016.06.021.
8. Elkaim, E., Neven, B., Bruneau, J., Mitsui-Sekinaka, K., Stanislas, A., Heurtier, L., et al. Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase delta syndrome 2: a cohort study. J Allergy Clin Immunol 138 (2016), 210–218.e9.
9. Nademi, Z., Slatter, M.A., Dvorak, C.C., Neven, B., Fischer, A., Suarez, F., et al. Hematopoietic stem cell transplant in patients with activated PI3K delta syndrome. J Allergy Clin Immunol, 2016 [Epub ahead of print]. http://dx.doi.org/10.1016/j.jaci.2016.09.040.
10. Rao VK, Christ AD, Su H, Kashyap A, Webster S, Sediva A, et al. Successful clinical study of Leniolisib (CDZ173), a small molecule PI3K-delta inhibitor in patients with APDS/PASLI. Presented at: ESID 17th Biennial Meeting; Barcelona, Spain; 2016.
11. Krummel, M.F., Allison, J.P., CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 183 (1996), 2533–2540.
12. Herrero-Beaumont, G., Martinez Calatrava, M.J., Castaneda, S., Abatacept mechanism of action: concordance with its clinical profile. Reumatol Clin 8 (2012), 78–83.
13. Kuehn, H.S., Ouyang, W., Lo, B., Deenick, E.K., Niemela, J.E., Avery, D.T., et al. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science 345 (2014), 1623–1627.
14. Schubert, D., Bode, C., Kenefeck, R., Hou, T.Z., Wing, J.B., Kennedy, A., et al. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med 20 (2014), 1410–1416.
15. Lee, S., Moon, J.S., Lee, C.R., Kim, H.E., Baek, S.M., Hwang, S., et al. Abatacept alleviates severe autoimmune symptoms in a patient carrying a de novo variant in CTLA-4. J Allergy Clin Immunol 137 (2016), 327–330.
16. Navarini, A.A., Hruz, P., Berger, C.T., Hou, T.Z., Schwab, C., Gabrysch, A., et al. Vedolizumab as a successful treatment of CTLA-4-associated autoimmune enterocolitis. J Allergy Clin Immunol, 2016 [Epub ahead of print].
17. Slatter, M.A., Engelhardt, K.R., Burroughs, L.M., Arkwright, P.D., Nademi, Z., Skoda-Smith, S., et al. Hematopoietic stem cell transplantation for CTLA4 deficiency. J Allergy Clin Immunol 138 (2016), 615–619.e1.
18. Lopez-Herrera, G., Tampella, G., Pan-Hammarstrom, Q., Herholz, P., Trujillo-Vargas, C.M., Phadwal, K., et al. Deleterious mutations in LRBA are associated with a syndrome of immune deficiency and autoimmunity. Am J Hum Genet 90 (2012), 986–1001.
19. Gamez-Diaz, L., August, D., Stepensky, P., Revel-Vilk, S., Seidel, M.G., Noriko, M., et al. The extended phenotype of LPS-responsive beige-like anchor protein (LRBA) deficiency. J Allergy Clin Immunol 137 (2016), 223–230.
20. Levy, E., Stolzenberg, M.C., Bruneau, J., Breton, S., Neven, B., Sauvion, S., et al. LRBA deficiency with autoimmunity and early onset chronic erosive polyarthritis. Clin Immunol 168 (2016), 88–93.
21. Alkhairy, O.K., Abolhassani, H., Rezaei, N., Fang, M., Andersen, K.K., Chavoshzadeh, Z., et al. Spectrum of phenotypes associated with mutations in LRBA. J Clin Immunol 36 (2016), 33–45.
22. Charbonnier, L.M., Janssen, E., Chou, J., Ohsumi, T.K., Keles, S., Hsu, J.T., et al. Regulatory T-cell deficiency and immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like disorder caused by loss-of-function mutations in LRBA. J Allergy Clin Immunol 135 (2015), 217–227.
23. Revel-Vilk, S., Fischer, U., Keller, B., Nabhani, S., Gamez-Diaz, L., Rensing-Ehl, A., et al. Autoimmune lymphoproliferative syndrome-like disease in patients with LRBA mutation. Clin Immunol 159 (2015), 84–92.
24. Lo, B., Zhang, K., Lu, W., Zheng, L., Zhang, Q., Kanellopoulou, C., et al. Autoimmune disease. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science 349 (2015), 436–440.
25. Seidel, M.G., Hirschmugl, T., Gamez-Diaz, L., Schwinger, W., Serwas, N., Deutschmann, A., et al. Long-term remission after allogeneic hematopoietic stem cell transplantation in LPS-responsive beige-like anchor (LRBA) deficiency. J Allergy Clin Immunol 135 (2015), 1384–1390 e1-8.
26. O'Shea, J.J., Plenge, R., JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity 36 (2012), 542–550.
27. Casanova, J.L., Holland, S.M., Notarangelo, L.D., Inborn errors of human JAKs and STATs. Immunity 36 (2012), 515–528.
28. Schwartz, D.M., Bonelli, M., Gadina, M., O'Shea, J.J., Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol 12 (2016), 25–36.
29. Dupuis, S., Jouanguy, E., Al-Hajjar, S., Fieschi, C., Al-Mohsen, I.Z., Al-Jumaah, S., et al. Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency. Nat Genet 33 (2003), 388–391.
30. Dupuis, S., Dargemont, C., Fieschi, C., Thomassin, N., Rosenzweig, S., Harris, J., et al. Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation. Science 293 (2001), 300–303.
31. Liu, L., Okada, S., Kong, X.F., Kreins, A.Y., Cypowyj, S., Abhyankar, A., et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med 208 (2011), 1635–1648.
32. van de Veerdonk, F.L., Plantinga, T.S., Hoischen, A., Smeekens, S.P., Joosten, L.A., Gilissen, C., et al. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N Engl J Med 365 (2011), 54–61.
33. Toubiana, J., Okada, S., Hiller, J., Oleastro, M., Lagos Gomez, M., Aldave Becerra, J.C., et al. Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype. Blood 127 (2016), 3154–3164.
34. Kumar, N., Hanks, M.E., Chandrasekaran, P., Davis, B.C., Hsu, A.P., Van Wagoner, N.J., et al. Gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation-related primary immunodeficiency is associated with disseminated mucormycosis. J Allergy Clin Immunol 134 (2014), 236–239.
35. Uzel, G., Sampaio, E.P., Lawrence, M.G., Hsu, A.P., Hackett, M., Dorsey, M.J., et al. Dominant gain-of-function STAT1 mutations in FOXP3 wild-type immune dysregulation-polyendocrinopathy-enteropathy-X-linked-like syndrome. J Allergy Clin Immunol 131 (2013), 1611–1623.
36. Sampaio, E.P., Hsu, A.P., Pechacek, J., Bax, H.I., Dias, D.L., Paulson, M.L., et al. Signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations and disseminated coccidioidomycosis and histoplasmosis. J Allergy Clin Immunol 131 (2013), 1624–1634.
37. Depner, M., Fuchs, S., Raabe, J., Frede, N., Glocker, C., Doffinger, R., et al. The extended clinical phenotype of 26 patients with chronic mucocutaneous candidiasis due to gain-of-function mutations in STAT1. J Clin Immunol 36 (2016), 73–84.
38. Zheng, J., van de Veerdonk, F.L., Crossland, K.L., Smeekens, S.P., Chan, C.M., Al Shehri, T., et al. Gain-of-function STAT1 mutations impair STAT3 activity in patients with chronic mucocutaneous candidiasis (CMC). Eur J Immunol 45 (2015), 2834–2846.
39. Ma, C.S., Wong, N., Rao, G., Avery, D.T., Torpy, J., Hambridge, T., et al. Monogenic mutations differentially affect the quantity and quality of T follicular helper cells in patients with human primary immunodeficiencies. J Allergy Clin Immunol 136 (2015), 993–1006.e1.
40. Romberg, N., Morbach, H., Lawrence, M.G., Kim, S., Kang, I., Holland, S.M., et al. Gain-of-function STAT1 mutations are associated with PD-L1 overexpression and a defect in B-cell survival. J Allergy Clin Immunol 131 (2013), 1691–1693.
41. Aldave, J.C., Cachay, E., Nunez, L., Chunga, A., Murillo, S., Cypowyj, S., et al. A 1-year-old girl with a gain-of-function STAT1 mutation treated with hematopoietic stem cell transplantation. J Clin Immunol 33 (2013), 1273–1275.
42. Hirahara, K., Schwartz, D., Gadina, M., Kanno, Y., O'Shea, J.J., Targeting cytokine signaling in autoimmunity: back to the future and beyond. Curr Opin Immunol 43 (2016), 89–97.
43. Roskoski, R. Jr., Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases. Pharmacol Res 111 (2016), 784–803.
44. Higgins, E., Al Shehri, T., McAleer, M.A., Conlon, N., Feighery, C., Lilic, D., et al. Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation. J Allergy Clin Immunol 135 (2015), 551–553.
45. Weinacht, K.G.C., Alroqi, F., Plant, A., Qiao, Q., Wu, H., Ma, C., et al. Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel STAT1 gain of function mutation. J Allergy Clin Immunol, 2017, 10.1016/j.jaci.2016.11.022.
46. Flanagan, S.E., Haapaniemi, E., Russell, M.A., Caswell, R., Lango Allen, H., De Franco, E., et al. Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease. Nat Genet 46 (2014), 812–814.
47. Haapaniemi, E.M., Kaustio, M., Rajala, H.L., van Adrichem, A.J., Kainulainen, L., Glumoff, V., et al. Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3. Blood 125 (2015), 639–648.
48. Milner, J.D., Vogel, T.P., Forbes, L., Ma, C.A., Stray-Pedersen, A., Niemela, J.E., et al. Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations. Blood 125 (2015), 591–599.
49. Haddad, E., STAT3: too much may be worse than not enough!. Blood 125 (2015), 583–584.
50. Koskela, H.L., Eldfors, S., Ellonen, P., van Adrichem, A.J., Kuusanmaki, H., Andersson, E.I., et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 366 (2012), 1905–1913.
51. Palmer, D.C., Restifo, N.P., Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function. Trends Immunol 30 (2009), 592–602.
52. Freeman, A.F., Holland, S.M., Clinical manifestations of hyper IgE syndromes. Dis Markers 29 (2010), 123–130.
53. Chandrasekaran, P., Zimmerman, O., Paulson, M., Sampaio, E.P., Freeman, A.F., Sowerwine, K.J., et al. Distinct mutations at the same positions of STAT3 cause either loss or gain of function. J Allergy Clin Immunol 138 (2016), 1222–1224.e2.
54. Camporeale, A., Poli, V., IL-6, IL-17 and STAT3: a holy trinity in auto-immunity?. Front Biosci 17 (2012), 2306–2326.
55. Kane, A., Deenick, E.K., Ma, C.S., Cook, M.C., Uzel, G., Tangye, S.G., STAT3 is a central regulator of lymphocyte differentiation and function. Curr Opin Immunol 28 (2014), 49–57.
56. Hernandez, P.A., Gorlin, R.J., Lukens, J.N., Taniuchi, S., Bohinjec, J., Francois, F., et al. Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease. Nat Genet 34 (2003), 70–74.
57. McCormick, P.J., Segarra, M., Gasperini, P., Gulino, A.V., Tosato, G., Impaired recruitment of Grk6 and beta-Arrestin 2 causes delayed internalization and desensitization of a WHIM syndrome-associated CXCR4 mutant receptor. PLoS One, 4, 2009, e8102.
58. Sugiyama, T., Kohara, H., Noda, M., Nagasawa, T., Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 25 (2006), 977–988.
59. Ma, Q., Jones, D., Springer, T.A., The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment. Immunity 10 (1999), 463–471.
60. Kawai, T., Malech, H.L., WHIM syndrome: congenital immune deficiency disease. Curr Opin Hematol 16 (2009), 20–26.
61. Gulino, A.V., Moratto, D., Sozzani, S., Cavadini, P., Otero, K., Tassone, L., et al. Altered leukocyte response to CXCL12 in patients with warts hypogammaglobulinemia, infections, myelokathexis (WHIM) syndrome. Blood 104 (2004), 444–452.
62. McDermott, D.H., Gao, J.L., Liu, Q., Siwicki, M., Martens, C., Jacobs, P., et al. Chromothriptic cure of WHIM syndrome. Cell 160 (2015), 686–699.
63. McDermott, D.H., Lopez, J., Deng, F., Liu, Q., Ojode, T., Chen, H., et al. AMD3100 is a potent antagonist at CXCR4(R334X), a hyperfunctional mutant chemokine receptor and cause of WHIM syndrome. J Cell Mol Med 15 (2011), 2071–2081.
64. Bilgin, Y.M., de Greef, G.E., Plerixafor for stem cell mobilization: the current status. Curr Opin Hematol 23 (2016), 67–71.
65. Dale, D.C., Bolyard, A.A., Kelley, M.L., Westrup, E.C., Makaryan, V., Aprikyan, A., et al. The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome. Blood 118 (2011), 4963–4966.
66. McDermott, D.H., Liu, Q., Ulrick, J., Kwatemaa, N., Anaya-O'Brien, S., Penzak, S.R., et al. The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome. Blood 118 (2011), 4957–4962.
67. McDermott, D.H., Liu, Q., Velez, D., Lopez, L., Anaya-O'Brien, S., Ulrick, J., et al. A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor. Blood 123 (2014), 2308–2316.